Zhejiang Yong Tai Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference cad5a54937
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
14 acceptance records as first applicant, grouped into 7 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Tadalafil Tablets 2 records · Latest accepted 2025/06/04
Generic · 2
Vonoprazan Fumarate Tablets 4 records · Latest accepted 2025/04/16
Supplement · 2Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500764 | Supplement | 2025/04/16 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2500763 | Supplement | 2025/04/16 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300466 | Generic | 2023/02/11 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300465 | Generic | 2023/02/11 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
西格列汀二甲双胍片(I) · No verified English name 1 records · Latest accepted 2023/10/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302712 | Generic | 2023/10/12 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II) 1 records · Latest accepted 2023/10/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302714 | Generic | 2023/10/12 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
Sitagliptin Phosphate Tablets 3 records · Latest accepted 2022/09/03
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201451 | Generic | 2022/09/03 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201450 | Generic | 2022/09/03 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2201449 | Generic | 2022/09/03 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
Esomeprazole Magnesium Enteric-Coated Capsules 2 records · Latest accepted 2022/06/24
Generic · 2
Moxifloxacin Hydrochloride Tablets 1 records · Latest accepted 2022/01/17
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2200068 | Generic | 2022/01/17 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Tadalafil Tablets | CYHS2501964 | Generic | 2025/06/04 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
| Tadalafil Tablets | CYHS2501963 | Generic | 2025/06/04 | Zhejiang Yong Tai Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
18 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Vonoprazan Fumarate Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20253482 | 2025/03/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vonoprazan Fumarate Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20253481 | 2025/03/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 西格列汀二甲双胍片(I) · No verified English name | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20253198 | 2025/01/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sitagliptin Phosphate and Metformin Hydrochloride Tablets (II) | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20253199 | 2025/01/14 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sitagliptin Phosphate Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20244051 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sitagliptin Phosphate Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20244049 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Moxifloxacin Hydrochloride Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20244077 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Sitagliptin Phosphate Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20244050 | 2024/06/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Esomeprazole Magnesium Enteric-Coated Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20243920 | 2024/06/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Esomeprazole Magnesium Enteric-Coated Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20243919 | 2024/06/04 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Aripiprazole Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223562 | 2022/08/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Aripiprazole Tablets | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223563 | 2022/08/10 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Duloxetine Hydrochloride Enteric Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223362 | 2022/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Duloxetine Hydrochloride Enteric Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223361 | 2022/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Duloxetine Hydrochloride Enteric Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223360 | 2022/06/07 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Gabapentin Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223320 | 2022/05/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Gabapentin Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223321 | 2022/05/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Gabapentin Capsules | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Zhejiang Yong Tai Pharma Co., Ltd. romanized | 国药准字H20223322 | 2022/05/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
4 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 磷酸西格列汀 · No verified English name | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Y20210001177 | A | 2023/08/01 | CDE ↗ |
| 瑞舒伐他汀钙 · No verified English name | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Y20210000962 | A | 2023/07/28 | CDE ↗ |
| 盐酸度洛西汀 · No verified English name | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Y20190021263 | A | 2023/07/31 | CDE ↗ |
| 奈韦拉平 · No verified English name | Zhejiang Yong Tai Pharma Co., Ltd. romanized | Y20190006471 | A | 2026/05/11 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.